• Home  / 
  • Biotech
  •  /  Marrone Bio Innovations Inc (NASDAQ:MBII) Stocks Spike After A Research Firm’s ‘Decent Pick’ Recommendation

Marrone Bio Innovations Inc (NASDAQ:MBII) Stocks Spike After A Research Firm’s ‘Decent Pick’ Recommendation

Marrone Bio Innovations Inc (NASDAQ:MBII) shares rose 21.7% last week after Zacks Equity Research recommended the David-based company’s stock as a decent pick in a strong industry. According to the research firm, the investors should consider the shares of American Company as an intriguing choice.

For the first time in the last two years, the shares of the company reached 58 cents to $3.25% and it was immediately after the report published by the research firm. On an average, the stock trades at a volume of 242, 280. But last weekend the stocks of Marrone traded at 1.86 million shares volume. The research firm makes use of mathematical models to provide the most accurate predictions. Apart from Zacks other research analysts also have predicted that the future earnings of the company will grow.

The Californian Company is engaged in developing biologically based products that replace chemical pesticides thereby contributing in improving the ecological balance of our planet and enabling organic food production. According to Zacks, Marrone is a chemical-diversified industry and ranks at the 49th spot among the 250 industries.

Marrone Begins 2018 Healthier Than Ever

Marrone is a leader manufacturer of bio-based pest management and plant health products that are used for agriculture. These products are also used for turf and ornamental and water treatment markets. The company recently came out with its financial result for the fourth quarter of the last year.

The company seems to have started the current year on a positive note with its CEO, Dr. Pam Marrone saying that they are beginning 2018 healthier than ever. She said that the company has eliminated most of its debt and hence capital-wise they are in a better position than last few years. This leaves the company with enough funds to operate the major tasks they have decided and carry on the developmental goals planned by the company management and also to reduce whatever debt is left with the company.

According to the CEO of Marrone, the main aim at present of the company is to increase the revenue growth and gross margins by introducing new improvements and managing the existing working capital.

About the author

Louisa Hendrickson

Hendrickson is the biotech writer for Investing News Center.

Click here to add a comment

Leave a comment: